BeyondSpring Raises $54 Million Via Private Placement and IPO

BeyondSpring, a New York City-China biopharma, completed a $54 million capital raise via a $3.5 million IPO and a $50.8 private placement, both at $20 per share. The transactions value BeyondSpring at $434 million. The private placement was led by two China investment firms, Sangel Star Biomedical and HuaRong TianZe, who are affiliates of current BeyondSpring investors. BeyondSpring has one candidate, plinabulin, in a China clinical trial, as a treatment for non-small cell lung cancer and chemotherapy-induced neutropenia. More details.... Stock Symbol: (NSDQ: BYSI) Share this with colleagues: // //